This webcast presents the development of a vaccine production process against the Influenza A H1N1 subtype using the recently developed Nuvia HP-Q Anion Exchange Chromatography Resin. The focus of this work was to develop an efficient and cost-effective process while maintaining product quality and safety. High purity and good overall yields were achieved with this single-step purification. The purification step used here is scalable and can be adapted for large-scale production, making the process an efficient downstream process for Influenza A H1N1 vaccine production.

Previous post

Advantages of Multiplexing with Bio-Plex Assays

Next post

Advanced Cancer Therapeutics: Increasing Efficacy and Specificity and Reducing Toxicity